Indian drugmaker Marion Biotech halts manufacture of cough syrup, probe underway
Dec 29, 2022, 17:55 IST
Indian Pharma company Marion Biotech Pvt Ltd has halted the production of cough syrup following allegations by Uzbekistan that at least 18 children died in the country after consuming the medicine.
A joint inspection of the manufacturer's Noida facility was carried out by the teams of the Uttar Pradesh Drug Control Department and CDSCO.
The Central Drugs Standard Control Organisation (CDSCO) is in contact with the national drug regulator of Uzbekistan regarding the matter.
"Immediately on receipt of the information, joint inspection of the NOIDA facility of the manufacturer, Marion Biotech, was carried out by UP Drug Control and CDSCO team and further action as appropriate would be initiated based on the inspection report," said the Union health ministry on Thursday.
The samples of the cough syrup have been taken from the manufacturing premises and sent to Regional Drugs Testing Laboratory (RDTL), Chandigarh for testing.
Meanwhile, Marion Biotech Pharma company has said that it has sent samples of the said cough syrup for testing and has also halted the production of the product.
Hasan, the Legal Head of Marion Biotech, expressed grief over the deaths on behalf of the company and said that an inquiry into the matter was being conducted by the government.
He added that samples were collected and action would be taken on the basis of the report.
Marion Biotech is a licensed manufacturer and holds a license for manufacturing Dok1 Max syrup and Tablet for export purposes granted by Drugs Controller, Uttar Pradesh.
Uzbekistan's health ministry, on Tuesday, said that 18 children suffering from an acute respiratory disease died after taking excessive doses of cough syrup Dok 1 Max, manufactured by Marion Biotech.
SEE ALSO:
Urgent need to develop antibiotics for newborns say global experts
Nirmala Sitharaman discharged from AIIMS
Advertisement
A joint inspection of the manufacturer's Noida facility was carried out by the teams of the Uttar Pradesh Drug Control Department and CDSCO.
The Central Drugs Standard Control Organisation (CDSCO) is in contact with the national drug regulator of Uzbekistan regarding the matter.
"Immediately on receipt of the information, joint inspection of the NOIDA facility of the manufacturer, Marion Biotech, was carried out by UP Drug Control and CDSCO team and further action as appropriate would be initiated based on the inspection report," said the Union health ministry on Thursday.
The samples of the cough syrup have been taken from the manufacturing premises and sent to Regional Drugs Testing Laboratory (RDTL), Chandigarh for testing.
Advertisement
Hasan, the Legal Head of Marion Biotech, expressed grief over the deaths on behalf of the company and said that an inquiry into the matter was being conducted by the government.
He added that samples were collected and action would be taken on the basis of the report.
Marion Biotech is a licensed manufacturer and holds a license for manufacturing Dok1 Max syrup and Tablet for export purposes granted by Drugs Controller, Uttar Pradesh.
Uzbekistan's health ministry, on Tuesday, said that 18 children suffering from an acute respiratory disease died after taking excessive doses of cough syrup Dok 1 Max, manufactured by Marion Biotech.
Advertisement
Experts say that cough syrups sometimes contain "unacceptable levels" of Diethylene Glycol and Ethylene Glycol. The syrup becomes harmful if there is even a slight difference in their quantity.SEE ALSO:
Urgent need to develop antibiotics for newborns say global experts
Nirmala Sitharaman discharged from AIIMS